What is it about?

Advanced prostate cancer can become resistant to treatments that lower testosterone. This is called castration-resistant prostate cancer. Immunotherapy, which helps the immune system recognize and attack cancer, has had limited success in this disease. This study explored whether radiation therapy could make immunotherapy work better when combined with medicines that block immune “brakes” or a cancer-related protein called PIM kinase. Researchers studied prostate cancer cells in the laboratory and prostate tumors in mice. Radiation increased signals that may help the immune system recognize cancer cells. In mice, combining radiation with two immune checkpoint treatments improved survival compared with single treatments or some two-treatment combinations. Another three-part approach (radiation, anti-PD-1 immunotherapy, and the PIM kinase inhibitor PIM447) also substantially improved survival and slowed tumor growth. The combination was associated with more cancer-fighting immune cells and fewer immune cells that can suppress an anti-cancer response. These findings suggest that radiation plus immunotherapy and PIM kinase inhibition may be a promising strategy for treatment-resistant prostate cancer. However, this was a laboratory and mouse study, not a clinical trial in people. More research is needed to confirm safety, determine the best treatment schedule, and learn whether this approach can benefit patients.

Featured Image

Why is it important?

Immunotherapy has transformed care for several cancers but has not yet helped most people with advanced prostate cancer. One reason is that prostate tumors can create an environment that prevents the immune system from mounting an effective attack. This study is timely because it examines a strategy designed to address several barriers at once: radiation may help reveal the cancer to the immune system, immune checkpoint treatments may strengthen immune-cell activity, and PIM kinase inhibition may reduce cells within the tumor that weaken the immune response. A unique aspect of this work is its focus on PIM kinase inhibition as part of a three-treatment approach with radiation and immunotherapy. The results also provide insight into how this combination may work by showing changes in immune cells within tumors, including increased cancer-fighting CD8-positive T cells and fewer immune-suppressing cells. Although these results are preliminary and require confirmation in clinical trials, they offer a practical scientific rationale for developing future treatment studies for castration-resistant prostate cancer. The work may help researchers identify more effective combination treatments and guide future studies of which patients and treatment schedules are most likely to benefit.

Perspectives

This work addresses a central challenge in advanced prostate cancer research: how to make immunotherapy more effective for a disease that has generally not responded well to immune-based treatments. Rather than relying on a single treatment, this study supports a biologically informed strategy that combines radiation therapy, immune checkpoint inhibition, and PIM kinase inhibition to activate anti-cancer immunity while counteracting immune suppression within the tumor. The most notable finding is that PIM447 added to radiation therapy and anti-PD-1 treatment substantially prolonged survival and delayed tumor growth in a mouse model of castration-resistant prostate cancer. The accompanying immune profiling also suggests why this may occur: combination treatment increased cancer-fighting CD8-positive T cells while reducing immune-suppressing cells, including myeloid-derived suppressor cells and tumor-associated macrophages. For patients with prostate cancer, these findings do not yet establish a new treatment option. However, they provide a rationale for developing carefully designed clinical studies of this combination approach, particularly for patients with treatment-resistant disease. Future work should confirm these results in additional prostate cancer models, identify biomarkers that may predict benefit, determine the safest dose and sequence of each treatment, and evaluate whether the approach can be translated into well-tolerated clinical trials.

Austin Kirschner
Vanderbilt University

Read the Original

This page is a summary of: Effects of Radiotherapy, Immune Checkpoint Inhibitors, and PIM Kinase Inhibition in Castration-Resistant Prostate Cancer, Current Cancer Drug Targets, April 2026, Bentham Science Publishers,
DOI: 10.2174/0115680096447552260409104759.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page